May 11, 2020 / 10:54 PM / 18 days ago

BRIEF-Neurocrine Biosciences Exercises Option To License Idorsia's Treatment For Pediatric Epilepsy

May 11 (Reuters) - Idorsia Ltd:

* NEUROCRINE BIOSCIENCES INC - EXERCISES OPTION TO LICENSE IDORSIA'S NOVEL TREATMENT FOR RARE PEDIATRIC EPILEPSY

* NEUROCRINE BIOSCIENCES - TO DEVELOP, COMMERCIALIZE ACT-709478, CLINICAL STAGE SELECTIVE T-TYPE CALCIUM CHANNEL BLOCKER FOR RARE PEDIATRIC EPILEPSY

* NEUROCRINE BIOSCIENCES INC - IDORSIA RECEIVES A $45 MILLION UPFRONT PAYMENT IN CASH

* NEUROCRINE BIOSCIENCES - IDORSIA WILL BE ENTITLED TO POTENTIAL DEVELOPMENT, REGULATORY MILESTONE PAYMENTS UP TO $365 MILLION,TIERED ROYALTIES ON NET SALES Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below